On-Demand Videos

Use these video resources for help in discussing shingles with your patients and to learn more about SHINGRIX.

HCP Effective Conversations
Watch an entertaining video on effective and not-effective ways to discuss shingles vaccination with patients in your office.

Pharmacist Effective Conversations
See the important role you can play in encouraging patients to get vaccinated against shingles at your pharmacy.

From Conversation to Vaccination
Pharmacists: Watch an informative and entertaining video on discussing shingles vaccination. See how you can motivate your patients to get vaccinated and how to address any concerns.

Webinar Miniseries: EHR & Series Completion
Review best practices to leverage your electronic health record system to help you identify appropriate patients.

Webinar Miniseries: Cost & Coverage
Take a closer look at payer coverage and reimbursement support for SHINGRIX.

Pivotal Trials
Learn about the pivotal clinical trials from Professor Tony Cunningham, one of the principal investigators and authors of the articles on our clinical trials published in the New England Journal of Medicine.

Pivotal Trials Synopsis
A brief review of the key elements from the pivotal clinical trials.

Reconstitution
Review reconstitution instructions for SHINGRIX.

Mechanism of Action
View how SHINGRIX is uniquely formulated to overcome age-related decline in shingles immunity.

HCP Effective Conversations
Watch an entertaining video on effective and not-effective ways to discuss shingles vaccination with patients in your office.

Reconstitution
Review reconstitution instructions for SHINGRIX.

Mechanism of Action
View how SHINGRIX is uniquely formulated to overcome age-related decline in shingles immunity.

Pharmacist Effective Conversations
See the important role you can play in encouraging patients to get vaccinated against shingles at your pharmacy.

From Conversation to Vaccination
Pharmacists: Watch an informative and entertaining video on discussing shingles vaccination. See how you can motivate your patients to get vaccinated and how to address any concerns.

Reconstitution
Review reconstitution instructions for SHINGRIX.

Mechanism of Action
View how SHINGRIX is uniquely formulated to overcome age-related decline in shingles immunity.

You may also be interested in:

Our library of resources includes handouts for patients, plus pocket and reference guides for you and your staff.

Talk to your patients about what to expect, including common adverse reactions.

See what CDC says about SHINGRIX.

 

CDC=Centers for Disease Control and Prevention.

  • See Video References

    References for HCP Effective Conversations: 1. United States Parachute Association. Demographics. Available at: https://uspa.org/Find/FAQs/Demographics. Accessed May 9, 2019. 2. Kilgore PE, Kruszon-Moran D, Seward JF, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol. 2003;70(suppl 1):S111-S118. 3. Centers for Disease Control and Prevention. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2008;57(RR-5):1-30. 4. Centers for Disease Control and Prevention. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. MMWR. 2018;67(3):103-108. 5. Prescribing Information for SHINGRIX. 6. Managed Markets Insight & Technology, LLC, database as of September 2018. 7. Centers for Medicare and Medicaid Services. Medicare Part D Vaccines. Available at: https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNProducts/Downloads/Vaccines-Part-D-Factsheet-ICN908764.pdf. Updated December 2020. Accessed December 11, 2019.

    References for Pharmacist Effective Conversations: 1. Prescribing Information for SHINGRIX. 2. Kilgore PE, Kruszon-Moran D, Seward JF, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol. 2003;70(suppl 1):S111-S118. 3. Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med. 2007;356(13):1338-1343. 4. Centers for Disease Control and Prevention. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2008;57(RR-5):1-30. 5. Levin MJ. Immune senescence and vaccines to prevent herpes zoster in older persons. Curr Opin Immunol. 2012;24(4):494-500. 6. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6):e004833. 7. Managed Markets Insight & Technology, LLC, database as of September 2018. 8. Centers for Medicare and Medicaid Services. Medicare Part D Vaccines. Available at: https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNProducts/Downloads/Vaccines-Part-D-Factsheet-ICN908764.pdf. Updated December 2020. Accessed December 11, 2019.

    References for From Conversation to Vaccination: 1. Mahalingam R, Wellish M, Wolf W, et al. Latent varicella-zoster viral DNA in human trigeminal and thoracic ganglia. N Engl J Med. 1990;323(10):627-631. 2. Lungu O, Annunziato PW, Gershon A, et al. Reactivated and latent varicella-zoster virus in human dorsal root ganglia. Proc Natl Acad Sci USA. 1995;92(24):10980-10984. 3. Furuta Y, Takasu T, Fukuda S, et al. Detection of varicella-zoster virus DNA in human geniculate ganglia by polymerase chain reaction. J Infect Dis. 1992;166(5):1157-1159. 4. Weinberg A, Lazar AA, Zerbe GO, et al. Influence of age and nature of primary infection on varicella-zoster virus—specific cell-mediated immune responses. J Infect Dis. 2010;201(7):1024-1030. 5. Centers for Disease Control and Prevention. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2008;57(RR-5):1-30. 6. Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med. 2007;356(13):1338-1343. 7. Levin MJ. Immune senescence and vaccines to prevent herpes zoster in older persons. Curr Opin Immunol. 2012;24(4):494-500. 8. Kilgore PE, Kruszon-Moran D, Seward JF, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol. 2003;70(suppl 1):S111-S118. 9. Chlibek R, Smetana J, Pauksens K, et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine. 2014;32(15):1745-1753. 10. Patterson-Bartlett J, Levin MJ, Lang N, Schödel FP, Vessey R, Weinberg A. Phenotypic and functional characterization of ex vivo T cell responses to the live attenuated herpes zoster vaccine. Vaccine. 2007;25(41):7087-7093. 11. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6):e004833. 12. Prescribing Information for SHINGRIX. 13. Yawn BP, Saddier P, Wollan PC, St. Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341-1349. 14. Centers for Disease Control and Prevention. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. MMWR. 2018;67(3):103-108. 15. Managed Markets Insight & Technology, LLC, database as of June 2020.

    References for Webinar Miniseries: EHR & Series Completion: Please see references included within video.

    References for Webinar Miniseries: Administration: Please see references included within video.

    References for Webinar Miniseries: Cost & Coverage: Please see references included within video.

    References for Pivotal Trials Video: 1. Centers for Disease Control and Prevention. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2008;57(RR-5):1-30. 2. Chlibek R, Smetana J, Pauksens K, et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine. 2014;32(15):1745-1753. 3. Cunningham AL, Dworkin RH. The management of post-herpetic neuralgia. BMJ. 2000;321(7264):778-779. 4. Cunningham AL, Lal H, Kovac M, et al, for the ZOE-70 Study Group. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019-1032. 5. Kilgore PE, Kruszon-Moran D, Seward JF, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol. 2003;70(suppl 1):S111-S118. 6. Lal H, Cunningham AL, Godeaux O, et al, for the ZOE-50 Study Group. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087-2096. 7. Leroux-Roels G, Marchant A, Levy J, et al. Impact of adjuvants on CD4+ T cell and B cell responses to a protein antigen vaccine: results from a phase II, randomized, multicenter trial. Clin Immunol. 2016;169:16-27. 8. Malavige GN, Jones L, Black AP, Ogg GS. Varicella zoster virus glycoprotein E-specific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors. Clin Exp Immunol. 2008;152(3):522-531. 9. NEJM Group. Notable Articles of 2016: A Collection of Important Studies From the Past Year as Selected by NEJM Editors. Waltham, MA: Massachusetts Medical Society; 2016. 10. Oxman MN, Levin MJ, Johnson GR, et al, for the Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271-2284. 11. Schmader K. Herpes zoster in older adults. Clin Infect Dis. 2001;32(10):1481-1486. 12. Prescribing Information for SHINGRIX.

    References for Pivotal Trials Synopsis Video: 1. Lal H, Cunningham AL, Godeaux O, et al, for the ZOE-50 Study Group. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087-2096. 2. Cunningham AL, Lal H Kovac M, et al, for the ZOE-70 Study Group. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019-1032. 3. Chlibek R, Smetana J, Pauksens K, et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine. 2014;32(15):1745-1753. 4. Prescribing Information for SHINGRIX.

    Reference for Reconstitution Video: 1. Prescribing Information for SHINGRIX.

    References for Mechanism of Action Video: 1. Centers for Disease Control and Prevention. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2008;57(RR-5):1-30. 2. Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med. 2007;356(13):1338-1343. 3. Tseng HF, Harpaz R, Luo Y, et al. Declining effectiveness of herpes zoster vaccine in adults aged ≥60 years. J Infect Dis. 2016;213(12):1872-1875. 4. Chlibek R, Smetana J, Pauksens K, et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine. 2014;32(15):1745-1753. 5. Prescribing Information for SHINGRIX. 6. Lal H, Cunningham AL, Godeaux O, et al, for the ZOE-50 Study Group. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087-2096. 7. Cunningham AL, Lal H, Kovac M, et al, for the ZOE-70 Study Group. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019-1032. 8. Dendouga N, Fochesato M, Lockman L, Mossman S, Giannini SL. Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice. Vaccine. 2012;30(20):3126-3135. 9. Chlibek R, Pauskens K, Rombo L, et al. Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults. Vaccine. 2016;34(6):863-868.